Evidence map›Paper›PMID 31049365›Full record

ArticleOpen forum infectious diseases2019

A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study.

Kathleen M Ward, Oluwaseun Falade-Nwulia, Juhi Moon, Catherine G Sutcliffe, Sherilyn Brinkley, Taryn Haselhuhn, Stephanie Katz, Kayla Herne, Lilian Arteaga, Shruti H Mehta and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02402218 (CHAMPS Study), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02402218 nacompletednot on this map

CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS

TypeinterventionalSponsorJohns Hopkins UniversityRan2015 to 2017Enrolled144ConditionsHepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency VirusArmsUsual care plus peer-mentors, Usual care plus incentives, Usual Care
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2023
    Review
  17. Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Kathleen M WardDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Oluwaseun Falade-NwuliaDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Juhi MoonDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Catherine G SutcliffeDepartment of Epidemiology, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Sherilyn BrinkleyDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Taryn HaselhuhnDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Stephanie KatzDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Kayla HerneDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Lilian ArteagaDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Shruti H MehtaDepartment of Epidemiology, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Carl LatkinDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Robert K BroonerDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland.
Mark S SulkowskiDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.ORCID 0000-0002-2145-6352
Johns Hopkins University · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
NCATS NIH HHS UL1 TR001079NIAID NIH HHS P30 AI094189NIDA NIH HHS K23 DA041294NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA016065NIDA NIH HHS R37 DA013806NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

backgroundDespite access to direct-acting antivirals, barriers to a hepatitis C virus (HCV) cure persist, especially among persons living with human immunodeficiency virus (HIV) (PLWH) who use drugs. Interventions such as peer mentors or cash incentives may improve the care continuum.

methodsThe CHAMPS (Chronic HepAtitis C Management to ImProve OutcomeS) study randomized 144 PLWH, recruited from an outpatient clinic, with substance use disorders into three treatment groups: usual care (UC) (n = 36), UC plus cash incentives (n = 54), and UC plus peer mentors (n = 54) to evaluate HCV treatment uptake and cure. All participants received 12-weeks of ledipasvir/sofosbuvir (LDV/SOF). Trained peer mentors had well-controlled HIV and HCV. Cash incentives were contingent on visit attendance (maximum $220). The primary endpoint was HCV treatment initiation; secondary endpoints included sustained virologic response (SVR) and HCV reinfection.

resultsThe majority of participants were male (61%), Black (93%), and unemployed (85%). Depression and active drug and alcohol use were common. Overall, 110 of 144 (76%) participants initiated LDV/SOF. Although treatment initiation rates were higher in PLWH randomized to peers (83%, 45 of 54) or cash (76%, 41 of 54) compared to UC (67%, 24 of 36), these differences were not statistically significant (

conclusionAfter removal of system barriers, one-third of PLWH in UC did not initiate HCV treatment. Among those who initiated, SVR rates were high. Research involving PLWH who use drugs should focus on overcoming barriers to treatment initiation. CLINICAL TRIAL INFORMATION: The registration data for the trial are in the ClinicalTrials.gov database, number NCT02402218.

Indexed as

cash incentiveshepatitis C virushuman immunodeficiency viruspeer mentorsubstance use disorders

Identifiers

PMID31049365
PMCPMC6488268
OpenAlexW2937892391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.